-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MMyqs1NMBwOv6fh6WNkbrfrDHef5ryITvHITUnPHJUPPwcZ7jE5jRQVcKMQFSNdu
 IHn+s2K11NKTiru1mejn6Q==

<SEC-DOCUMENT>0000912057-97-020189.txt : 19970613
<SEC-HEADER>0000912057-97-020189.hdr.sgml : 19970613
ACCESSION NUMBER:		0000912057-97-020189
CONFORMED SUBMISSION TYPE:	RW
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		19970612
SROS:			NASD

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			APOLLO BIOPHARMACEUTICS INC
		CENTRAL INDEX KEY:			0001029495
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043160456
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		RW
		SEC ACT:		
		SEC FILE NUMBER:	001-12813
		FILM NUMBER:		97623078

	BUSINESS ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BUILDING 200 SUITE 2200
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		6176217154

	MAIL ADDRESS:	
		STREET 1:		ONE KENDALL SQUARE
		STREET 2:		BUILDING 200 SUITE 2200
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>RW
<SEQUENCE>1
<DESCRIPTION>SEC REGISTRATION WITHDRAWAL LETTER
<TEXT>

<PAGE>

                            Apollo BioPharmaceutics, Inc.
                            One Kendall Square, Suite 2200
                            Cambridge, Massachusetts 02139
                                           

                                     June 6, 1997

BY OVERNIGHT DELIVERY

Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, DC 20549

    Re:  Apollo BioPharmaceutics, Inc.
         Registration Statements on Form 8-A

Gentlemen and Ladies:

    Apollo BioPharmaceutics, Inc. (the "Company") hereby requests that the
Company's Registration Statement on Form 8-A, which was declared effective by
order of the Commission on March 27, 1997, be withdrawn effective immediately. 
The Company makes this request because a proposed initial public offering of the
Company's securities was abandoned by the lead underwriter subsequent to
effectiveness.

    If you have any questions regarding this request, please contact either
John J. Cheney, Esq. of Palmer & Dodge LLP at (617) 573-0563 or me at (617)
621-7154.

                             Sincerely,

                             APOLLO BIOPHARMACEUTICS, INC.


                             By:   /s/ Katherine Gordon, Ph.D.            
                                   ------------------------------------
                                   Katherine Gordon, Ph.D
                                   President and Chief Executive Officer

cc: Steven Brown (Nasdaq)
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----